カテゴリー： QYResearch, 世界, 医療/バイオ

世界の前立腺特異抗原（PSA）検査市場インサイト及び予測（ラジオイムノアッセイ、酵素イムノアッセイ）

◆英語タイトル：Global Prostate Specific Antigen (PSA) Testing Market Insights, Forecast to 2028

QYResearchが発行した調査報告書（QY22JLX09280）◆商品コード：QY22JLX09280
◆発行会社（リサーチ会社）：QYResearch
◆発行日：2022年7月（※2025年版があります。お問い合わせください。）
◆ページ数：114
◆レポート形式：英語 / PDF
◆納品方法：Eメール（受注後3営業日）
◆調査対象地域：グローバル
◆産業分野：医療
◆販売価格オプション（消費税別）
Single User（1名様閲覧用）USD4,900 ⇒換算￥744,800見積依頼/購入/質問フォーム
Multi User（5名様閲覧用）USD7,350 ⇒換算￥1,117,200見積依頼/購入/質問フォーム
Enterprise License（同一法人内共有可）USD9,800 ⇒換算￥1,489,600見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いに変更可）
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。

❖ レポートの概要 ❖

COVID-19のパンデミックにより、前立腺特異抗原（PSA）検査のグローバル市場規模は2022年にUS$xxxと推定され、調査期間中のCAGRはxxx％で、2028年までに再調整された規模はUS$xxxになると予測されています。この医療危機による経済変化を十分に考慮すると、2021年に前立腺特異抗原（PSA）検査の世界市場のxxx％を占める「ラジオイムノアッセイ」タイプは、2028年までにUS$xxxの規模になり、パンデミック後の修正xxx％CAGRで成長すると予測されています。一方、「病院」セグメントは、この予測期間を通じてxxx％のCAGRに変更されます。
前立腺特異抗原（PSA）検査の中国市場規模は2021年にUS$xxxと分析されており、米国とヨーロッパの市場規模はそれぞれUS$xxxとUS$xxxです。米国の割合は2021年にxxx％であり、中国とヨーロッパはそれぞれxxx％とxxx％です。中国の割合は2028年にxxx％に達し、対象期間を通じてxxx％のCAGRを記録すると予測されています。日本、韓国、東南アジアはアジアで注目市場であり、今後6年間のCAGRはそれぞれxxx％、xxx％、xxx％になる見通しです。ヨーロッパの前立腺特異抗原（PSA）検査市場については、ドイツは2028年までにUS$xxxに達すると予測されており、予測期間中のCAGRはxxx％になる見通しです。

前立腺特異抗原（PSA）検査のグローバル主要企業には、Cleveland Diagnostics、Abbott、Siemens Healthineers、DiaSorin、Roche Holding AG、Beckman Coulter、Mediwatch(LABORIE)、Boditech、Bristol Myers Squibb、GE Healthcare、Endocare、GlaxoSmith Kline、Anixa Biosciences、Ortho Clinical、Fujirebio、Merckなどがあります。2021年、世界のトップ5プレイヤーは売上ベースで約xxx％の市場シェアを占めています。

前立腺特異抗原（PSA）検査市場は、種類と用途によって区分されます。世界の前立腺特異抗原（PSA）検査市場のプレーヤー、利害関係者、およびその他の参加者は、当レポートを有益なリソースとして使用することで優位に立つことができます。セグメント分析は、2017年～2028年期間のタイプ別および用途別の販売量、売上、予測に焦点を当てています。

【種類別セグメント】
ラジオイムノアッセイ、酵素イムノアッセイ

【用途別セグメント】
病院、クリニック、診断センター、研究所、その他

【掲載地域】
北米：アメリカ、カナダ
ヨーロッパ：ドイツ、フランス、イギリス、イタリア、ロシア
アジア太平洋：日本、中国、韓国、インド、オーストラリア、台湾、インドネシア、タイ、マレーシア
中南米：メキシコ、ブラジル、アルゼンチン
中東・アフリカ：トルコ、サウジアラビア、UAE

【目次（一部）】

・調査の範囲
- 前立腺特異抗原（PSA）検査製品概要
- 種類別市場（ラジオイムノアッセイ、酵素イムノアッセイ）
- 用途別市場（病院、クリニック、診断センター、研究所、その他）
- 調査の目的
・エグゼクティブサマリー
- 世界の前立腺特異抗原（PSA）検査販売量予測2017-2028
- 世界の前立腺特異抗原（PSA）検査売上予測2017-2028
- 前立腺特異抗原（PSA）検査の地域別販売量
- 前立腺特異抗原（PSA）検査の地域別売上
- 北米市場
- ヨーロッパ市場
- アジア太平洋市場
- 中南米市場
- 中東・アフリカ市場
・メーカーの競争状況
- 主要メーカー別前立腺特異抗原（PSA）検査販売量
- 主要メーカー別前立腺特異抗原（PSA）検査売上
- 主要メーカー別前立腺特異抗原（PSA）検査価格
- 競争状況の分析
- 企業M&A動向
・種類別市場規模（ラジオイムノアッセイ、酵素イムノアッセイ）
- 前立腺特異抗原（PSA）検査の種類別販売量
- 前立腺特異抗原（PSA）検査の種類別売上
- 前立腺特異抗原（PSA）検査の種類別価格
・用途別市場規模（病院、クリニック、診断センター、研究所、その他）
- 前立腺特異抗原（PSA）検査の用途別販売量
- 前立腺特異抗原（PSA）検査の用途別売上
- 前立腺特異抗原（PSA）検査の用途別価格
・北米市場
- 北米の前立腺特異抗原（PSA）検査市場規模（種類別、用途別）
- 主要国別の前立腺特異抗原（PSA）検査市場規模（アメリカ、カナダ）
・ヨーロッパ市場
- ヨーロッパの前立腺特異抗原（PSA）検査市場規模（種類別、用途別）
- 主要国別の前立腺特異抗原（PSA）検査市場規模（ドイツ、フランス、イギリス、イタリア、ロシア）
・アジア太平洋市場
- アジア太平洋の前立腺特異抗原（PSA）検査市場規模（種類別、用途別）
- 主要国別の前立腺特異抗原（PSA）検査市場規模（日本、中国、韓国、インド、オーストラリア、台湾、インドネシア、タイ、マレーシア）
・中南米市場
- 中南米の前立腺特異抗原（PSA）検査市場規模（種類別、用途別）
- 主要国別の前立腺特異抗原（PSA）検査市場規模（メキシコ、ブラジル、アルゼンチン）
・中東・アフリカ市場
- 中東・アフリカの前立腺特異抗原（PSA）検査市場規模（種類別、用途別）
- 主要国別の前立腺特異抗原（PSA）検査市場規模（トルコ、サウジアラビア）
・企業情報
Cleveland Diagnostics、Abbott、Siemens Healthineers、DiaSorin、Roche Holding AG、Beckman Coulter、Mediwatch(LABORIE)、Boditech、Bristol Myers Squibb、GE Healthcare、Endocare、GlaxoSmith Kline、Anixa Biosciences、Ortho Clinical、Fujirebio、Merck
・産業チェーン及び販売チャネル分析
- 前立腺特異抗原（PSA）検査の産業チェーン分析
- 前立腺特異抗原（PSA）検査の原材料
- 前立腺特異抗原（PSA）検査の生産プロセス
- 前立腺特異抗原（PSA）検査の販売及びマーケティング
- 前立腺特異抗原（PSA）検査の主要顧客
・マーケットドライバー、機会、課題、リスク要因分析
- 前立腺特異抗原（PSA）検査の産業動向
- 前立腺特異抗原（PSA）検査のマーケットドライバー
- 前立腺特異抗原（PSA）検査の課題
- 前立腺特異抗原（PSA）検査の阻害要因
・主な調査結果

Market Analysis and Insights: Global Prostate Specific Antigen (PSA) Testing Market
The global Prostate Specific Antigen (PSA) Testing market size is projected to reach US$ million by 2028, from US$ million in 2021, at a CAGR of % during 2022-2028.
Fully considering the economic change by this health crisis, Radioimmunoassay accounting for % of the Prostate Specific Antigen (PSA) Testing global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR from 2022 to 2028. While Hospitals segment is altered to an % CAGR throughout this forecast period.
China Prostate Specific Antigen (PSA) Testing market size is valued at US$ million in 2021, while the North America and Europe Prostate Specific Antigen (PSA) Testing are US$ million and US$ million, severally. The proportion of the North America is % in 2021, while China and Europe are % and % respectively, and it is predicted that China proportion will reach % in 2028, trailing a CAGR of % through the analysis period 2022-2028. Japan, South Korea, and Southeast Asia are noteworthy markets in Asia, with CAGR %, %, and % respectively for the next 6-year period. As for the Europe Prostate Specific Antigen (PSA) Testing landscape, Germany is projected to reach US$ million by 2028 trailing a CAGR of % over the forecast period 2022-2028.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Prostate Specific Antigen (PSA) Testing market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Prostate Specific Antigen (PSA) Testing market in terms of revenue.
Overall, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Prostate Specific Antigen (PSA) Testing market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Prostate Specific Antigen (PSA) Testing market.
Global Prostate Specific Antigen (PSA) Testing Scope and Market Size
Prostate Specific Antigen (PSA) Testing market is segmented by players, region (country), by Type and by Application. Players, stakeholders, and other participants in the global Prostate Specific Antigen (PSA) Testing market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application for the period 2017-2028.
Segment by Type
Radioimmunoassay
Enzyme Immunoassay
Segment by Application
Hospitals
Clinics
Diagnostic Centers
Research Institute
Others
By Company
Cleveland Diagnostics
Abbott
Siemens Healthineers
DiaSorin
Roche Holding AG
Beckman Coulter
Mediwatch(LABORIE)
Boditech
Bristol Myers Squibb
GE Healthcare
Endocare
GlaxoSmith Kline
Anixa Biosciences
Ortho Clinical
Fujirebio
Merck
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA

❖ レポートの目次 ❖

1 Report Business Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Prostate Specific Antigen (PSA) Testing Market Size Growth Rate by Type, 2017 VS 2021 VS 2028
1.2.2 Radioimmunoassay
1.2.3 Enzyme Immunoassay
1.3 Market by Application
1.3.1 Global Prostate Specific Antigen (PSA) Testing Market Size Growth Rate by Application, 2017 VS 2021 VS 2028
1.3.2 Hospitals
1.3.3 Clinics
1.3.4 Diagnostic Centers
1.3.5 Research Institute
1.3.6 Others
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global Prostate Specific Antigen (PSA) Testing Market Perspective (2017-2028)
2.2 Prostate Specific Antigen (PSA) Testing Growth Trends by Region
2.2.1 Prostate Specific Antigen (PSA) Testing Market Size by Region: 2017 VS 2021 VS 2028
2.2.2 Prostate Specific Antigen (PSA) Testing Historic Market Size by Region (2017-2022)
2.2.3 Prostate Specific Antigen (PSA) Testing Forecasted Market Size by Region (2023-2028)
2.3 Prostate Specific Antigen (PSA) Testing Market Dynamics
2.3.1 Prostate Specific Antigen (PSA) Testing Industry Trends
2.3.2 Prostate Specific Antigen (PSA) Testing Market Drivers
2.3.3 Prostate Specific Antigen (PSA) Testing Market Challenges
2.3.4 Prostate Specific Antigen (PSA) Testing Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Prostate Specific Antigen (PSA) Testing Players by Revenue
3.1.1 Global Top Prostate Specific Antigen (PSA) Testing Players by Revenue (2017-2022)
3.1.2 Global Prostate Specific Antigen (PSA) Testing Revenue Market Share by Players (2017-2022)
3.2 Global Prostate Specific Antigen (PSA) Testing Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Prostate Specific Antigen (PSA) Testing Revenue
3.4 Global Prostate Specific Antigen (PSA) Testing Market Concentration Ratio
3.4.1 Global Prostate Specific Antigen (PSA) Testing Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Prostate Specific Antigen (PSA) Testing Revenue in 2021
3.5 Prostate Specific Antigen (PSA) Testing Key Players Head office and Area Served
3.6 Key Players Prostate Specific Antigen (PSA) Testing Product Solution and Service
3.7 Date of Enter into Prostate Specific Antigen (PSA) Testing Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Prostate Specific Antigen (PSA) Testing Breakdown Data by Type
4.1 Global Prostate Specific Antigen (PSA) Testing Historic Market Size by Type (2017-2022)
4.2 Global Prostate Specific Antigen (PSA) Testing Forecasted Market Size by Type (2023-2028)
5 Prostate Specific Antigen (PSA) Testing Breakdown Data by Application
5.1 Global Prostate Specific Antigen (PSA) Testing Historic Market Size by Application (2017-2022)
5.2 Global Prostate Specific Antigen (PSA) Testing Forecasted Market Size by Application (2023-2028)
6 North America
6.1 North America Prostate Specific Antigen (PSA) Testing Market Size (2017-2028)
6.2 North America Prostate Specific Antigen (PSA) Testing Market Size by Type
6.2.1 North America Prostate Specific Antigen (PSA) Testing Market Size by Type (2017-2022)
6.2.2 North America Prostate Specific Antigen (PSA) Testing Market Size by Type (2023-2028)
6.2.3 North America Prostate Specific Antigen (PSA) Testing Market Share by Type (2017-2028)
6.3 North America Prostate Specific Antigen (PSA) Testing Market Size by Application
6.3.1 North America Prostate Specific Antigen (PSA) Testing Market Size by Application (2017-2022)
6.3.2 North America Prostate Specific Antigen (PSA) Testing Market Size by Application (2023-2028)
6.3.3 North America Prostate Specific Antigen (PSA) Testing Market Share by Application (2017-2028)
6.4 North America Prostate Specific Antigen (PSA) Testing Market Size by Country
6.4.1 North America Prostate Specific Antigen (PSA) Testing Market Size by Country (2017-2022)
6.4.2 North America Prostate Specific Antigen (PSA) Testing Market Size by Country (2023-2028)
6.4.3 United States
6.4.4 Canada
7 Europe
7.1 Europe Prostate Specific Antigen (PSA) Testing Market Size (2017-2028)
7.2 Europe Prostate Specific Antigen (PSA) Testing Market Size by Type
7.2.1 Europe Prostate Specific Antigen (PSA) Testing Market Size by Type (2017-2022)
7.2.2 Europe Prostate Specific Antigen (PSA) Testing Market Size by Type (2023-2028)
7.2.3 Europe Prostate Specific Antigen (PSA) Testing Market Share by Type (2017-2028)
7.3 Europe Prostate Specific Antigen (PSA) Testing Market Size by Application
7.3.1 Europe Prostate Specific Antigen (PSA) Testing Market Size by Application (2017-2022)
7.3.2 Europe Prostate Specific Antigen (PSA) Testing Market Size by Application (2023-2028)
7.3.3 Europe Prostate Specific Antigen (PSA) Testing Market Share by Application (2017-2028)
7.4 Europe Prostate Specific Antigen (PSA) Testing Market Size by Country
7.4.1 Europe Prostate Specific Antigen (PSA) Testing Market Size by Country (2017-2022)
7.4.2 Europe Prostate Specific Antigen (PSA) Testing Market Size by Country (2023-2028)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Prostate Specific Antigen (PSA) Testing Market Size (2017-2028)
8.2 Asia-Pacific Prostate Specific Antigen (PSA) Testing Market Size by Type
8.2.1 Asia-Pacific Prostate Specific Antigen (PSA) Testing Market Size by Type (2017-2022)
8.2.2 Asia-Pacific Prostate Specific Antigen (PSA) Testing Market Size by Type (2023-2028)
8.2.3 Asia-Pacific Prostate Specific Antigen (PSA) Testing Market Share by Type (2017-2028)
8.3 Asia-Pacific Prostate Specific Antigen (PSA) Testing Market Size by Application
8.3.1 Asia-Pacific Prostate Specific Antigen (PSA) Testing Market Size by Application (2017-2022)
8.3.2 Asia-Pacific Prostate Specific Antigen (PSA) Testing Market Size by Application (2023-2028)
8.3.3 Asia-Pacific Prostate Specific Antigen (PSA) Testing Market Share by Application (2017-2028)
8.4 Asia-Pacific Prostate Specific Antigen (PSA) Testing Market Size by Region
8.4.1 Asia-Pacific Prostate Specific Antigen (PSA) Testing Market Size by Region (2017-2022)
8.4.2 Asia-Pacific Prostate Specific Antigen (PSA) Testing Market Size by Region (2023-2028)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia
9 Latin America
9.1 Latin America Prostate Specific Antigen (PSA) Testing Market Size (2017-2028)
9.2 Latin America Prostate Specific Antigen (PSA) Testing Market Size by Type
9.2.1 Latin America Prostate Specific Antigen (PSA) Testing Market Size by Type (2017-2022)
9.2.2 Latin America Prostate Specific Antigen (PSA) Testing Market Size by Type (2023-2028)
9.2.3 Latin America Prostate Specific Antigen (PSA) Testing Market Share by Type (2017-2028)
9.3 Latin America Prostate Specific Antigen (PSA) Testing Market Size by Application
9.3.1 Latin America Prostate Specific Antigen (PSA) Testing Market Size by Application (2017-2022)
9.3.2 Latin America Prostate Specific Antigen (PSA) Testing Market Size by Application (2023-2028)
9.3.3 Latin America Prostate Specific Antigen (PSA) Testing Market Share by Application (2017-2028)
9.4 Latin America Prostate Specific Antigen (PSA) Testing Market Size by Country
9.4.1 Latin America Prostate Specific Antigen (PSA) Testing Market Size by Country (2017-2022)
9.4.2 Latin America Prostate Specific Antigen (PSA) Testing Market Size by Country (2023-2028)
9.4.3 Mexico
9.4.4 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Prostate Specific Antigen (PSA) Testing Market Size (2017-2028)
10.2 Middle East & Africa Prostate Specific Antigen (PSA) Testing Market Size by Type
10.2.1 Middle East & Africa Prostate Specific Antigen (PSA) Testing Market Size by Type (2017-2022)
10.2.2 Middle East & Africa Prostate Specific Antigen (PSA) Testing Market Size by Type (2023-2028)
10.2.3 Middle East & Africa Prostate Specific Antigen (PSA) Testing Market Share by Type (2017-2028)
10.3 Middle East & Africa Prostate Specific Antigen (PSA) Testing Market Size by Application
10.3.1 Middle East & Africa Prostate Specific Antigen (PSA) Testing Market Size by Application (2017-2022)
10.3.2 Middle East & Africa Prostate Specific Antigen (PSA) Testing Market Size by Application (2023-2028)
10.3.3 Middle East & Africa Prostate Specific Antigen (PSA) Testing Market Share by Application (2017-2028)
10.4 Middle East & Africa Prostate Specific Antigen (PSA) Testing Market Size by Country
10.4.1 Middle East & Africa Prostate Specific Antigen (PSA) Testing Market Size by Country (2017-2022)
10.4.2 Middle East & Africa Prostate Specific Antigen (PSA) Testing Market Size by Country (2023-2028)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE
11 Key Players Profiles
11.1 Cleveland Diagnostics
11.1.1 Cleveland Diagnostics Company Details
11.1.2 Cleveland Diagnostics Business Overview
11.1.3 Cleveland Diagnostics Prostate Specific Antigen (PSA) Testing Introduction
11.1.4 Cleveland Diagnostics Revenue in Prostate Specific Antigen (PSA) Testing Business (2017-2022)
11.1.5 Cleveland Diagnostics Recent Developments
11.2 Abbott
11.2.1 Abbott Company Details
11.2.2 Abbott Business Overview
11.2.3 Abbott Prostate Specific Antigen (PSA) Testing Introduction
11.2.4 Abbott Revenue in Prostate Specific Antigen (PSA) Testing Business (2017-2022)
11.2.5 Abbott Recent Developments
11.3 Siemens Healthineers
11.3.1 Siemens Healthineers Company Details
11.3.2 Siemens Healthineers Business Overview
11.3.3 Siemens Healthineers Prostate Specific Antigen (PSA) Testing Introduction
11.3.4 Siemens Healthineers Revenue in Prostate Specific Antigen (PSA) Testing Business (2017-2022)
11.3.5 Siemens Healthineers Recent Developments
11.4 DiaSorin
11.4.1 DiaSorin Company Details
11.4.2 DiaSorin Business Overview
11.4.3 DiaSorin Prostate Specific Antigen (PSA) Testing Introduction
11.4.4 DiaSorin Revenue in Prostate Specific Antigen (PSA) Testing Business (2017-2022)
11.4.5 DiaSorin Recent Developments
11.5 Roche Holding AG
11.5.1 Roche Holding AG Company Details
11.5.2 Roche Holding AG Business Overview
11.5.3 Roche Holding AG Prostate Specific Antigen (PSA) Testing Introduction
11.5.4 Roche Holding AG Revenue in Prostate Specific Antigen (PSA) Testing Business (2017-2022)
11.5.5 Roche Holding AG Recent Developments
11.6 Beckman Coulter
11.6.1 Beckman Coulter Company Details
11.6.2 Beckman Coulter Business Overview
11.6.3 Beckman Coulter Prostate Specific Antigen (PSA) Testing Introduction
11.6.4 Beckman Coulter Revenue in Prostate Specific Antigen (PSA) Testing Business (2017-2022)
11.6.5 Beckman Coulter Recent Developments
11.7 Mediwatch(LABORIE)
11.7.1 Mediwatch(LABORIE) Company Details
11.7.2 Mediwatch(LABORIE) Business Overview
11.7.3 Mediwatch(LABORIE) Prostate Specific Antigen (PSA) Testing Introduction
11.7.4 Mediwatch(LABORIE) Revenue in Prostate Specific Antigen (PSA) Testing Business (2017-2022)
11.7.5 Mediwatch(LABORIE) Recent Developments
11.8 Boditech
11.8.1 Boditech Company Details
11.8.2 Boditech Business Overview
11.8.3 Boditech Prostate Specific Antigen (PSA) Testing Introduction
11.8.4 Boditech Revenue in Prostate Specific Antigen (PSA) Testing Business (2017-2022)
11.8.5 Boditech Recent Developments
11.9 Bristol Myers Squibb
11.9.1 Bristol Myers Squibb Company Details
11.9.2 Bristol Myers Squibb Business Overview
11.9.3 Bristol Myers Squibb Prostate Specific Antigen (PSA) Testing Introduction
11.9.4 Bristol Myers Squibb Revenue in Prostate Specific Antigen (PSA) Testing Business (2017-2022)
11.9.5 Bristol Myers Squibb Recent Developments
11.10 GE Healthcare
11.10.1 GE Healthcare Company Details
11.10.2 GE Healthcare Business Overview
11.10.3 GE Healthcare Prostate Specific Antigen (PSA) Testing Introduction
11.10.4 GE Healthcare Revenue in Prostate Specific Antigen (PSA) Testing Business (2017-2022)
11.10.5 GE Healthcare Recent Developments
11.11 Endocare
11.11.1 Endocare Company Details
11.11.2 Endocare Business Overview
11.11.3 Endocare Prostate Specific Antigen (PSA) Testing Introduction
11.11.4 Endocare Revenue in Prostate Specific Antigen (PSA) Testing Business (2017-2022)
11.11.5 Endocare Recent Developments
11.12 GlaxoSmith Kline
11.12.1 GlaxoSmith Kline Company Details
11.12.2 GlaxoSmith Kline Business Overview
11.12.3 GlaxoSmith Kline Prostate Specific Antigen (PSA) Testing Introduction
11.12.4 GlaxoSmith Kline Revenue in Prostate Specific Antigen (PSA) Testing Business (2017-2022)
11.12.5 GlaxoSmith Kline Recent Developments
11.13 Anixa Biosciences
11.13.1 Anixa Biosciences Company Details
11.13.2 Anixa Biosciences Business Overview
11.13.3 Anixa Biosciences Prostate Specific Antigen (PSA) Testing Introduction
11.13.4 Anixa Biosciences Revenue in Prostate Specific Antigen (PSA) Testing Business (2017-2022)
11.13.5 Anixa Biosciences Recent Developments
11.14 Ortho Clinical
11.14.1 Ortho Clinical Company Details
11.14.2 Ortho Clinical Business Overview
11.14.3 Ortho Clinical Prostate Specific Antigen (PSA) Testing Introduction
11.14.4 Ortho Clinical Revenue in Prostate Specific Antigen (PSA) Testing Business (2017-2022)
11.14.5 Ortho Clinical Recent Developments
11.15 Fujirebio
11.15.1 Fujirebio Company Details
11.15.2 Fujirebio Business Overview
11.15.3 Fujirebio Prostate Specific Antigen (PSA) Testing Introduction
11.15.4 Fujirebio Revenue in Prostate Specific Antigen (PSA) Testing Business (2017-2022)
11.15.5 Fujirebio Recent Developments
11.16 Merck
11.16.1 Merck Company Details
11.16.2 Merck Business Overview
11.16.3 Merck Prostate Specific Antigen (PSA) Testing Introduction
11.16.4 Merck Revenue in Prostate Specific Antigen (PSA) Testing Business (2017-2022)
11.16.5 Merck Recent Developments
12 Analyst’s Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Author Details
13.3 Disclaimer



❖ 免責事項 ❖
http://www.globalresearch.jp/disclaimer
★リサーチレポート[ 世界の前立腺特異抗原（PSA）検査市場インサイト及び予測（ラジオイムノアッセイ、酵素イムノアッセイ）(Global Prostate Specific Antigen (PSA) Testing Market Insights, Forecast to 2028)]についてメールでお問い合わせはこちらでお願いします。
◆関連リサーチレポート◆
  • 前立腺特異抗原検査キットのグローバル市場予測2023-2029
  • 世界のICチップパッケージング・検査市場インサイト及び予測（BGA、LGA、SiP、FC、その他）
  • 世界のアレルギー診断・検査市場インサイト及び予測（吸入アレルゲン、食物アレルゲン、薬物アレルゲン、その他アレルゲン）
  • 世界の新型コロナウイルス感染症(COVID-19)抗原検査キット市場2022年：PCR、Qpcr
  • 世界のヒト白血球抗原検査市場2022年：分子アッセイ技術、非分子アッセイ技術